Abstract
Epilepsy is a common brain disease and preventing epilepsy is a very relevant public health concern and an urgent unmet need. Although 40 % of all epilepsy cases are thought to have acquired causes, there is a roadblock for successful prevention. Efforts to protect the brain from epileptogenic insults are severely hampered by our lack of biomarkers to identify the few percent at high risk meriting treatment among those exposed. Preventing brain injury has been moderately effective from around birth to middle age; however, the strategy has failed to stop a substantial increase over the last decades in symptomatic epilepsy in those aged 65 and above. The traditional concept of repurposing anti-seizure drugs used for symptomatic seizure relief to prevent the onset of epilepsy has completely failed up to now. More recently, however, hope is on the horizon with a search for biomarkers and discovery of a new class of agents, called anti-epileptogenic drugs, which were specifically developed for prevention of epilepsy.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Löscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev. 2010;62:668–700.
Dichter MA. Emerging concepts in the pathogenesis of epilepsy and epileptogenesis. Arch Neurol. 2009;66:443–7.
Löscher W, Hirsch LJ, Schmidt D. The enigma of the latent period in the development of symptomatic acquired epilepsy—traditional view versus new concepts. Epilepsy Behav. 2015;52(Pt A):78–92. An important article about the latent period as a window of therapeutic opportunity for preventions trial in epilepsy.
Sloviter RS, Bumanglag AV. Defining “epileptogenesis” and identifying “antiepileptogenic targets” in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. Neuropharmacology. 2012;69:3–15.
Temkin NR. Preventing and treating posttraumatic seizures: the human experience. Epilepsia. 2009;50 Suppl 2:10–3.
Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for antiepileptic drug discovery and development. Nat Rev Drug Discov. 2013;12:757–76.
Dreifuss FE. Prevention as it pertains to epilepsy. Arch Neurol. 1995;52(4):363–6.
Sillanpää M, Gissler M, Schmidt D. Efforts in epilepsy prevention in the last 40 years: lessons from a large nationwide study. JAMA Neurol. 2016;73(4):390–5. An important article showing that we failed to prevent epilepsy in people below age 65 and a massive increase in epilepsy in the elderly.
Agostini M. The prevention of epilepsy. JAMA Neurol. 2016;73(4):375–610.
Herman ST. Clinical trials for prevention of epileptogenesis. Epilepsy Res. 2006;68:35–8.
Sloviter RS. Progress on the issue of excitotoxic injury modification vs. real neuroprotection; implications for post-traumatic epilepsy. Neuropharmacology. 2011;61(5-6):1048–50.
Mani R, Pollard J, Dichter MA. Human clinical trials in antiepileptogenesis. Neurosci Lett. 2011;497(3):251–6.
Schmidt D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. Epilept Disord. 2012;14:105–13.
Pitkänen A, Engel Jr J. Past and present definitions of epileptogenesis and its biomarkers. Neurotherapeutics. 2014;11(2):231–41.
Pitkänen A, Löscher W, Vezzani A, et al. Advances in the development of biomarkers for epilepsy. Lancet Neurol. 2016;15(8):843–56. A good overview showing where how we stand in the discovery of biomarkers for epilepsy development.
Baulac M, de Boer H, Elger C, et al. Epilepsy priorities in Europe: a report of the ILAE-IBE Epilepsy Advocacy Europe Task Force. Epilepsia. 2015;56(11):1687–95.
Schmidt D. Chapter 5 antiepileptic drug development. In: Shorvon SD, Perucca E, Engel Jr J, editors. Treatment of epilepsy. 4th ed. Newark: Wiley-Blackwell; 2015. p. 61–74.
Schmidt D, Friedman D, Dichter MA. Anti-epileptogenic clinical trial designs in epilepsy: issues and options. Neurotherapeutics. 2014;11(2):401–11.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Dieter Schmidt and Matti Sillanpää declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Epilepsy
Rights and permissions
About this article
Cite this article
Schmidt, D., Sillanpää, M. Prevention of Epilepsy: Issues and Innovations. Curr Neurol Neurosci Rep 16, 95 (2016). https://doi.org/10.1007/s11910-016-0695-9
Published:
DOI: https://doi.org/10.1007/s11910-016-0695-9